my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3 more
NicOx S.A. announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis. Following two phase 2a studies that were conducted by TOPIGEN with TPI 1020 in patients with as more
NicOx S.A. announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). This follows the su more
NicOx S.A. announced that it has raised a total of approximately €100 million via a two-step capital increase. The second step of this capital increase was the completion of a rights issue, launched on November 25th 2009, which raised total gross proceeds of €69.9 million through the issuance of 20, more
BB BIOTECH AG (BB BIOTECH) is a Switzerland based investment company, principally engaged in investing in biotech companies related to oncology, cardiovascular diseases, infectious diseases and autoimmune diseases. The company’s portfolio includes Actelion, Gilead, Celgene, Vertex Pharmaceuticals, G more
Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. We forecast and explain the commercial opportunities there. Our report gives you revenue predictions for ophthalmic treatments from 20 more
Introduction Global Market Directs pharmaceuticals report, NicOx SA - Product Pipeline Review - Q1 2011 provides data on the companys research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and more
About Us R&D Overview Collaborations News & Events Contact Us Investors Working For Chroma Content on this page requires a newer version of Adobe Flash Player. Chroma’s management team has an exemplary record in taking multiple novel research programmes from target to market, combined with exten more
Home | Online Store | Français Search Corporate Profile > History > History 2002 Corporate Profile Events and Conferences Our Products Careers Contact Us Site Map Values, Mission and Vision Message from the President and CEO Management Team History History 1994-82 History 1995 History 19 more
Home biotissue-tec-com Biotech & more Archive for the ‘News’ Category European Biotech News Posted on August 27th, 2011 by admin | No Comments » Shares of the biotech firm NicOx have been pummeled after an EU panel rejects their anti-inflammatory treatment naproxcinod. The French company said it w more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
